AMPH - Amphastar Pharmaceuticals Inc Stock Price, Fair Value and News

42.44USD+0.30 (+0.71%)Market Closed

Market Summary

USD42.44+0.30

Market Closed

0.71%

AMPH Alerts

1 major insider sales recently.

AMPH Stock Price

View Fullscreen

AMPH RSI Chart

AMPH Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

13.42

Price/Sales (Trailing)

3.07

EV/EBITDA

Price/Free Cashflow

12.9

AMPH Price/Sales (Trailing)

AMPH Profitability

Operating Margin

54.33%

EBT Margin

27.46%

Return on Equity

23.01%

Return on Assets

9.83%

Free Cashflow Yield

7.75%

AMPH Fundamentals

AMPH Revenue

Revenue (TTM)

676.2M

Rev. Growth (Yr)

22.72%

Rev. Growth (Qtr)

-3.52%

AMPH Earnings

Earnings (TTM)

154.7M

Earnings Growth (Yr)

65.86%

Earnings Growth (Qtr)

19.38%

Breaking Down AMPH Revenue

Last 7 days

6.0%

Last 30 days

3.8%

Last 90 days

2.5%

Trailing 12 Months

-31.3%

How does AMPH drawdown profile look like?

AMPH Financial Health

Current Ratio

2.18

Debt/Equity

0.88

Debt/Cashflow

0.33

AMPH Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

2.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	676.2M	0	0	0
2023	518.6M	540.9M	601.3M	644.4M
2022	455.1M	476.9M	484.9M	499.0M
2021	368.2M	384.0M	412.8M	437.8M
2020	327.3M	334.0M	337.3M	349.8M
2019	316.1M	324.1M	328.7M	322.4M
2018	241.9M	247.8M	265.4M	294.7M
2017	252.5M	249.6M	243.3M	240.2M
2016	254.0M	268.2M	268.5M	255.2M
2015	221.5M	226.3M	230.5M	251.5M
2014	222.6M	209.1M	209.5M	210.5M
2013	210.7M	217.0M	223.3M	229.7M
2012	0	0	0	204.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CEO	Dr. Yongfeng Zhang Ph.D.
WEBSITE	amphastar.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1615

Amphastar Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Amphastar Pharmaceuticals Inc? What does AMPH stand for in stocks?

AMPH is the stock ticker symbol of Amphastar Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amphastar Pharmaceuticals Inc (AMPH)?

As of Thu Jul 25 2024, market cap of Amphastar Pharmaceuticals Inc is 2.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers.

Is Amphastar Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPH is over valued or under valued. Whether Amphastar Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amphastar Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPH.

What is Amphastar Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, AMPH's PE ratio (Price to Earnings) is 13.32 and Price to Sales (PS) ratio is 3.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amphastar Pharmaceuticals Inc's stock?

In the past 10 years, Amphastar Pharmaceuticals Inc has provided 0.167 (multiply by 100 for percentage) rate of return.